CO2018005842A2 - Composición farmacéutica que comprende un potente inhibidor de urat 1 - Google Patents
Composición farmacéutica que comprende un potente inhibidor de urat 1Info
- Publication number
- CO2018005842A2 CO2018005842A2 CONC2018/0005842A CO2018005842A CO2018005842A2 CO 2018005842 A2 CO2018005842 A2 CO 2018005842A2 CO 2018005842 A CO2018005842 A CO 2018005842A CO 2018005842 A2 CO2018005842 A2 CO 2018005842A2
- Authority
- CO
- Colombia
- Prior art keywords
- urat
- potent
- inhibitor
- pharmaceutical composition
- compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/04—Drugs for disorders of the urinary system for urolithiasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Pain & Pain Management (AREA)
- Inorganic Chemistry (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente invención se refiere a composiciones farmacéuticas que contienen ácido 2-((3-(4-cianonaftalen-1-il)piridin-4-il)tio)-2-metilpropanoico o una sal farmacéuticamente aceptable (en lo sucesivo en el presente documento denominado "Agente "), más particularmente a composiciones administrables por vía oral que contienen el Agente; al uso de dichas composiciones como un medicamento; y a procesos para la preparación de dichas composiciones.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562264792P | 2015-12-08 | 2015-12-08 | |
PCT/EP2016/080111 WO2017097845A1 (en) | 2015-12-08 | 2016-12-07 | Pharmaceutical composition comprising a potent inhibitor of urat1 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2018005842A2 true CO2018005842A2 (es) | 2018-07-10 |
Family
ID=57517882
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2018/0005842A CO2018005842A2 (es) | 2015-12-08 | 2018-06-06 | Composición farmacéutica que comprende un potente inhibidor de urat 1 |
Country Status (20)
Country | Link |
---|---|
US (3) | US20180360761A1 (es) |
EP (1) | EP3386485A1 (es) |
JP (2) | JP6976946B2 (es) |
KR (1) | KR20180082613A (es) |
CN (1) | CN108289848A (es) |
AU (1) | AU2016368622B2 (es) |
BR (1) | BR112018011376A2 (es) |
CA (1) | CA3006167A1 (es) |
CL (1) | CL2018001510A1 (es) |
CO (1) | CO2018005842A2 (es) |
EA (1) | EA038828B9 (es) |
HK (2) | HK1253034A1 (es) |
IL (1) | IL259844B (es) |
MA (1) | MA43402A (es) |
MX (1) | MX2018006903A (es) |
PE (1) | PE20181521A1 (es) |
PH (1) | PH12018501236A1 (es) |
SG (1) | SG11201804100UA (es) |
WO (1) | WO2017097845A1 (es) |
ZA (1) | ZA201804519B (es) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101988066B1 (ko) * | 2011-11-03 | 2019-09-27 | 아디아 바이오사이언스즈 인크. | 3,4-이치환된 피리딘 화합물, 이의 사용 방법 및 이를 포함하는 조성물 |
TWI780270B (zh) * | 2017-11-28 | 2022-10-11 | 靜岡縣公立大學法人 | 固體分散體 |
US20210338648A1 (en) * | 2018-10-01 | 2021-11-04 | Astrazeneca Ab | Methods and compositions for reducing serum uric acid |
CN112057429B (zh) * | 2019-06-11 | 2023-04-07 | 上海京新生物医药有限公司 | 雷西纳德控释药物组合物 |
KR20220035156A (ko) * | 2019-07-16 | 2022-03-21 | 아스트라제네카 아베 | 베리누라드를 포함하는 과량 방출 저항성 약제학적 조성물 |
CN113368073A (zh) * | 2020-07-23 | 2021-09-10 | 太阳升(亳州)生物医药科技有限公司 | 制备用于降低血液尿酸水平的药物制剂的方法 |
CN113368032A (zh) * | 2020-07-23 | 2021-09-10 | 太阳升(亳州)生物医药科技有限公司 | 药物组合物、口服固体制剂及其制备方法和用途 |
CN113368067A (zh) * | 2020-07-23 | 2021-09-10 | 太阳升(亳州)生物医药科技有限公司 | 制备用于降低血液尿酸水平的口服药物片剂的方法 |
WO2022162021A1 (en) | 2021-01-27 | 2022-08-04 | Astrazeneca Ab | Verinurad compositions and methods of use |
AU2021464980A1 (en) * | 2021-09-17 | 2024-05-02 | Hinova Pharmaceuticals Inc. | Quinoline compound sustained-release tablet and preparation method therefor |
WO2024076999A2 (en) * | 2022-10-04 | 2024-04-11 | Engrail Therapeutics, Inc. | Gabaa receptor modulators and uses thereof |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2010416B2 (de) * | 1970-03-05 | 1979-03-29 | Hoechst Ag, 6000 Frankfurt | Oral anwendbare Arzneiform mit Retardwirkung |
JPH04234812A (ja) * | 1990-03-16 | 1992-08-24 | Yamanouchi Pharmaceut Co Ltd | 持続性製剤用顆粒 |
BRPI0607198A2 (pt) * | 2005-02-15 | 2016-11-01 | Wyeth Corp | composição, uso da composição método de tratamento doenças, e, embalagem farmacêutica |
RU2435573C2 (ru) * | 2005-07-28 | 2011-12-10 | ШИР ЭлЭлСи | Фармацевтические составы на основе гуанфацина, подходящие для ежедневного введения в виде единичной дозированной формы |
US20090104266A1 (en) * | 2005-09-15 | 2009-04-23 | Tobias Jung | 3-(2-dimethylaminomethylcy clohexyl)phenol retard formulation |
WO2011126852A2 (en) * | 2010-03-30 | 2011-10-13 | Ardea Biosciences, Inc. | Treatment of gout |
CA2802407C (en) * | 2010-06-15 | 2018-01-23 | Ardea Biosciences, Inc. | Treatment of gout and hyperuricemia |
AR081930A1 (es) * | 2010-06-16 | 2012-10-31 | Ardea Biosciences Inc | Compuestos de tioacetato |
KR101988066B1 (ko) * | 2011-11-03 | 2019-09-27 | 아디아 바이오사이언스즈 인크. | 3,4-이치환된 피리딘 화합물, 이의 사용 방법 및 이를 포함하는 조성물 |
-
2016
- 2016-12-07 EP EP16808626.2A patent/EP3386485A1/en active Pending
- 2016-12-07 KR KR1020187019068A patent/KR20180082613A/ko not_active Application Discontinuation
- 2016-12-07 BR BR112018011376A patent/BR112018011376A2/pt not_active Application Discontinuation
- 2016-12-07 JP JP2018529601A patent/JP6976946B2/ja active Active
- 2016-12-07 CN CN201680071604.2A patent/CN108289848A/zh active Pending
- 2016-12-07 AU AU2016368622A patent/AU2016368622B2/en not_active Ceased
- 2016-12-07 CA CA3006167A patent/CA3006167A1/en not_active Abandoned
- 2016-12-07 MA MA043402A patent/MA43402A/fr unknown
- 2016-12-07 WO PCT/EP2016/080111 patent/WO2017097845A1/en active Application Filing
- 2016-12-07 MX MX2018006903A patent/MX2018006903A/es unknown
- 2016-12-07 SG SG11201804100UA patent/SG11201804100UA/en unknown
- 2016-12-07 EA EA201891267A patent/EA038828B9/ru unknown
- 2016-12-07 US US15/781,693 patent/US20180360761A1/en not_active Abandoned
- 2016-12-07 PE PE2018001088A patent/PE20181521A1/es unknown
-
2018
- 2018-06-06 CL CL2018001510A patent/CL2018001510A1/es unknown
- 2018-06-06 IL IL259844A patent/IL259844B/en unknown
- 2018-06-06 CO CONC2018/0005842A patent/CO2018005842A2/es unknown
- 2018-06-08 PH PH12018501236A patent/PH12018501236A1/en unknown
- 2018-07-06 ZA ZA2018/04519A patent/ZA201804519B/en unknown
- 2018-09-27 HK HK18112413.4A patent/HK1253034A1/zh unknown
- 2018-11-29 HK HK18115313.8A patent/HK1256256A1/zh unknown
-
2020
- 2020-08-31 US US17/007,041 patent/US20210113472A1/en not_active Abandoned
-
2021
- 2021-11-10 JP JP2021182955A patent/JP2022033758A/ja active Pending
-
2022
- 2022-06-23 US US17/808,390 patent/US20230011269A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
IL259844B (en) | 2022-04-01 |
JP2022033758A (ja) | 2022-03-02 |
JP6976946B2 (ja) | 2021-12-08 |
EA038828B9 (ru) | 2021-12-03 |
US20230011269A1 (en) | 2023-01-12 |
ZA201804519B (en) | 2022-04-28 |
BR112018011376A2 (pt) | 2018-12-04 |
SG11201804100UA (en) | 2018-06-28 |
WO2017097845A1 (en) | 2017-06-15 |
MX2018006903A (es) | 2018-11-09 |
EA038828B1 (ru) | 2021-10-26 |
PE20181521A1 (es) | 2018-09-24 |
KR20180082613A (ko) | 2018-07-18 |
MA43402A (fr) | 2018-10-17 |
HK1253034A1 (zh) | 2019-06-06 |
CA3006167A1 (en) | 2017-06-15 |
HK1256256A1 (zh) | 2019-09-20 |
EP3386485A1 (en) | 2018-10-17 |
US20210113472A1 (en) | 2021-04-22 |
IL259844A (en) | 2018-07-31 |
PH12018501236A1 (en) | 2019-02-18 |
CN108289848A (zh) | 2018-07-17 |
US20180360761A1 (en) | 2018-12-20 |
EA201891267A1 (ru) | 2019-01-31 |
CL2018001510A1 (es) | 2018-09-21 |
AU2016368622B2 (en) | 2022-09-08 |
JP2019501895A (ja) | 2019-01-24 |
AU2016368622A1 (en) | 2018-06-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2018005842A2 (es) | Composición farmacéutica que comprende un potente inhibidor de urat 1 | |
CL2017000379A1 (es) | Compuestos de pirrolopirimidina usados como agonistas del receptor de tipo toll. 7 (tlr7) | |
NI201600098A (es) | Composiciones farmacéuticas que comprenden azd9291 | |
NI201700011A (es) | 2-(morfolin-4-il)-1,7-naftiridinas. | |
ECSP18082774A (es) | Derivados aromáticos de sulfonamida | |
CL2018001199A1 (es) | Composiciones terapéuticas para el tratamiento del virus de inmunodeficiencia humana | |
CR20170411A (es) | Composiciones farmacéuticas que comprenden n-(3,5-dimetoxifenil)-n-(1-metiletil)-n-[3-(1-metil-1h-pirazol-4-il-quin oxalin-6-il]etano-1,2-diamina | |
CL2012002423A1 (es) | Método para tratar lupus nefritis activo que comprende administrar al paciente laquinimod o su sal sódica por vía oral; composición farmacéutica que comprende laquinimod y micofenolato mofetil. | |
PE20180411A1 (es) | Formulaciones farmaceuticas que comprenden tenofovir y emtricitabina | |
BR112015010791A2 (pt) | moduladores de gpr40 de di-hidropirazol | |
AR128459A2 (es) | Composición farmacéutica sólida comprimida por rodillo y el proceso para su fabricación | |
BR112018010107A2 (pt) | composição farmacêutica para o tratamento ou prevenção de nash | |
BR112015023878A2 (pt) | composto, composição farmacêutica, e, uso de um composto | |
CO2019004004A2 (es) | Composición farmacéutica y método para el tratamiento de la enfermedad del hígado graso no alcohólico | |
BR112015010271A8 (pt) | produto de comicronização, processo para o preparo de um produto de comicronização, composição farmacêutica e seus usos | |
CL2012003341A1 (es) | Composicion farmaceutica de administracion oral que compende bendamustina o un ester, una sal o un solvato de la misma, y un excipiente que es un agente tensioactivo no ionico e hidrofilico; combinacion farmaceutica; y su uso para el tratamiento de leucemia linfocitica cronica y el mieloma multiple, entre otras enfermedades. | |
CO2022008616A2 (es) | Composición farmacéutica oral que comprende compuesto de carbamato y método de preparación para la misma | |
BR112016009214A8 (pt) | uso de um composto para preparação de um medicamento para o tratamento de distrofia muscular e composição farmacêutica | |
BR112015021769A2 (pt) | composições farmacêuticas compreendendo um agente ativo | |
CO2018002046A2 (es) | Nueva composición oral de libreación retardada dual de dexlansoprazol | |
AR103219A1 (es) | Compuesto de (1h-indol-3-il)propan-1-ona, composición farmacéutica, combinación y mezcla que lo comprenden y su uso para la fabricación de un medicamento | |
CO2017000354A2 (es) | Desmopresina estabilizada | |
BR112017021589A2 (pt) | métodos para o tratamento de transtornos cardiovasculares | |
CU20180036A7 (es) | Composiciones terapéuticas para el tratamiento del virus de la inmunodeficiencia humana | |
MX2018007272A (es) | Composicion farmaceutica de liberacion pulsatil que comprende naftazona o una de sus sales. |